Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.

ABSTRACT:

Background and objectives

Cytochrome P450 2C9 (CYP2C9) is involved in the biotransformation of many commonly used drugs, and significant drug interactions have been reported for CYP2C9 substrates. Previously published physiologically based pharmacokinetic (PBPK) models of tolbutamide are based on an assumption that its metabolic clearance is exclusively through CYP2C9; however, many studies indicate that CYP2C9 metabolism is only responsible for 80-90% of the total clearance. Therefore, these models are not useful for predicting the magnitude of CYP2C9 drug-drug interactions (DDIs). This paper describes the development and verification of SimCYP^®-based PBPK models that accurately describe the human pharmacokinetics of tolbutamide when dosed alone or in combination with t

SUBMITTER: Perkins EJ 

PROVIDER: S-EPMC5956062 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature